Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma

Retinoids are an important component of neuroblastoma therapy at the stage of minimal residual disease, yet 40–50% of patients treated with 13‐cis‐retinoic acid (13‐cis‐RA) still relapse, indicating the need for more effective retinoid therapy. Vorinostat, or Suberoylanilide hydroxamic acid (SAHA),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Oncol
Hauptverfasser: Cheung, Belamy B., Tan, Owen, Koach, Jessica, Liu, Bing, Shum, Michael S.Y., Carter, Daniel R., Sutton, Selina, Po'uha, Sela T., Chesler, Louis, Haber, Michelle, Norris, Murray D., Kavallaris, Maria, Liu, Tao, O'Neill, Geraldine M., Marshall, Glenn M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2015
Schlagworte:
Research Papers
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528804/
https://ncbi.nlm.nih.gov/pubmed/25963741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.04.005
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge